Liquid biopsy has been introduced as a new diagnostic concept predicated on the analysis
of circulating tumour cells (CTCs) or circulating tumour-derived factors, in particular, cell-free …

Recent advances in diagnosis and treatment are enabling a more targeted approach to
treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit …

The isolation and analysis of circulating cell-free tumor DNA in plasma is a powerful tool with
considerable potential to improve clinical outcomes across multiple cancer types, including …

Colorectal cancer (CRC) is one of the most common malignancies in Western countries.
Over the last 20 years, and the last decade in particular, the clinical outcome for patients with …

Malignant tumors shed DNA into the circulation. The transient half-life of circulating tumor
DNA (ctDNA) may afford the opportunity to diagnose, monitor recurrence, and evaluate …

The inherent molecular heterogeneity of metastatic tumors and the ability of cancer
genomes to dynamically evolve are not properly captured by tissue specimens. Analysis of …

Circulating tumour DNA (ctDNA) analysis facilitates studies of tumour heterogeneity. Here
we employ CAPP-Seq ctDNA analysis to study resistance mechanisms in 43 non-small cell …

Precision medicine in the clinical management of cancer may be achieved through the
diagnostic platform called “liquid biopsy”. This method utilizes the detection of biomarkers in …

The development of noninvasive methods to detect and monitor tumors continues to be a
major challenge in oncology. We used digital polymerase chain reaction–based …

Circulating tumor DNA (ctDNA) is a promising biomarker for noninvasive assessment of
cancer burden, but existing ctDNA detection methods have insufficient sensitivity or patient …